Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.420
-0.030 (-2.07%)
Jun 8, 2026, 4:00 PM EDT - Market closed
Coherus Oncology Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 115.24 | 88.88 | 125.99 | 102.89 | 63.55 | 417.2 |
Short-Term Investments | 51.81 | 83.25 | - | 14.86 | 128.13 | - |
Cash & Short-Term Investments | 167.05 | 172.13 | 125.99 | 117.75 | 191.68 | 417.2 |
Cash Growth | 102.70% | 36.62% | 7.00% | -38.57% | -54.05% | -22.91% |
Accounts Receivable | 22.51 | 18.42 | 122.33 | 260.52 | 109.96 | 123.02 |
Inventory | 4.83 | 3.17 | 4.21 | 62.61 | 38.79 | 37.64 |
Other Current Assets | 11.65 | 12.99 | 89.06 | 34.76 | 40.8 | 24.46 |
Total Current Assets | 206.04 | 206.71 | 341.58 | 475.63 | 381.23 | 602.32 |
Net Property, Plant & Equipment | 1.09 | 1.35 | 2.58 | 5.12 | 8.75 | 7.81 |
Other Intangible Assets | 45.61 | 46.24 | 53.65 | 71.67 | 5.93 | 3.56 |
Goodwill | - | - | - | - | - | 3.56 |
Other Long-Term Assets | 13.28 | 4.05 | 50.73 | 77.18 | 84.93 | 65.64 |
Total Assets | 266.02 | 258.34 | 448.53 | 629.6 | 480.85 | 679.33 |
Accounts Payable | 11.48 | 9.92 | 28.46 | 35.22 | 11.53 | 16.16 |
Accrued Expenses | 120.85 | 130.47 | 254.53 | 296.55 | 127.17 | 149.17 |
Total Current Liabilities | 132.33 | 140.39 | 282.98 | 331.77 | 138.69 | 165.33 |
Long-Term Debt | 37.15 | 37.05 | 264.93 | 473.37 | 471.06 | 408.28 |
Long-Term Leases | 0.95 | 1.46 | 3.29 | 5.33 | 5.05 | 7.25 |
Other Long-Term Liabilities | 16.97 | 18.44 | 29.33 | 12.56 | 3.47 | 0.75 |
Total Long-Term Liabilities | 55.07 | 56.94 | 297.54 | 491.26 | 479.57 | 416.28 |
Total Liabilities | 187.4 | 197.33 | 580.52 | 823.03 | 618.27 | 581.61 |
Common Stock | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 1,500 | 1,444 | 1,419 | 1,386 | 1,204 | 1,148 |
Accumulated Other Comprehensive Income | -0.27 | -0.2 | -0.28 | -0.25 | -0.25 | -0.27 |
Retained Earnings | -1,421 | -1,383 | -1,551 | -1,580 | -1,342 | -1,050 |
Shareholders' Equity | 78.62 | 61.01 | -131.99 | -193.43 | -137.42 | 97.73 |
Total Liabilities & Equity | 266.02 | 258.34 | 448.53 | 629.6 | 480.85 | 679.33 |
Total Debt | 38.1 | 38.51 | 268.21 | 478.7 | 476.1 | 415.53 |
Net Cash (Debt) | 128.95 | 133.62 | -142.23 | -360.95 | -284.42 | 1.66 |
Net Cash Growth | -3.50% | - | - | - | - | -98.69% |
Net Cash Per Share | 1.05 | 1.14 | -1.24 | -3.83 | -3.66 | 0.02 |
Book Value | 78.62 | 61.01 | -131.99 | -193.43 | -137.42 | 97.73 |
Book Value Per Share | 0.64 | 0.52 | -1.15 | -2.05 | -1.77 | 1.30 |
Tangible Book Value | 33.01 | 14.78 | -185.64 | -265.1 | -143.35 | 90.6 |
Tangible Book Value Per Share | 0.27 | 0.13 | -1.62 | -2.82 | -1.85 | 1.20 |